IBA Reports Full Year 2023 Results - Seite 3

• 18 Other Accelerators systems sold in 2023 (2022: 36 systems), with a strong uptick in Equipment and Services revenues
• Seven PT rooms sold, comprising one ProteusPLUS¹ and three ProteusONE¹ systems sold, and the restoration of an existing three-room solution in the US (2022: 17 rooms)
• 33 PT projects under construction or installation at the end of the period
• Continued good progress of IBA and SCK CEN’s joint venture PanTera for the production of actinium-225, with collaborations secured with supplier TerraPower and post-period end, with Bayer and another undisclosed customer
• Post-period end, Dosimetry product offering and US footprint strengthened with acquisition of Radcal Corporation, an X-ray imaging specialist
• B Corp recertification ongoing
• Henri de Romrée appointed as Deputy CEO

***ENDS***

IBA’s management team will host a hybrid event, including a conference call and webcast conducted in English, to present the full year results, followed by a Q&A session.

The conference call will be held on Thursday, 21 March 2024 at 3pm CET / 2pm GMT / 10am ET / 7am PT as a Teams webinar and can be accessed online via this link.

If you would like to join by phone only, please dial (Phone conference ID 204 708 166#):


Belgium:                     [phone]
UK:                             [phone]
NL:                              [phone]
LU:                              [phone]
US:                             [phone]
FR:                              [phone]